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Soluble guanylate cyclase (sGC), the primarymediator of nitric oxide (NO) bioactivity, exists
as reduced (NO-sensitive) and oxidized (NO-insensitive) forms. We tested the hypothe-
sis that the cardiovascular protective effects of NO-insensitive sGC activation would be
potentiated under conditions of oxidative stress compared to those of NO-sensitive sGC
stimulation. The cardiovascular effects of the NO-insensitive sGC activator GSK2181236A
[a low, non-depressor dose, and a high dose which lowered mean arterial pressure (MAP)
by 5–10mmHg] and those of equi-efﬁcacious doses of the NO-sensitive sGC stimu-
lator BAY 60-4552 were assessed in (1) Sprague Dawley rats during coronary artery
ischemia/reperfusion (I/R) and (2) spontaneously hypertensive stroke prone rats (SHR-SP)
on a high salt/fat diet (HSFD). In I/R, neither compound reduced infarct size 24 h after
reperfusion. In SHR-SP, HSFD increased MAP, urine output, microalbuminuria, and mor-
tality, caused left ventricular hypertrophy with preserved ejection fraction, and impaired
endothelium-dependent vasorelaxation. The low dose of BAY 60-4552, but not that of
GSK2181236A, decreased urine output, and improved survival. Conversely, the low dose of
GSK2181236A, but not that of BAY 60-4552, attenuated the development of cardiac hyper-
trophy. The high doses of both compounds similarly attenuated cardiac hypertrophy and
improved survival. In addition to these effects, the high dose of BAY 60-4552 reduced urine
output and microalbuminuria and attenuated the increase in MAP to a greater extent than
did GSK2181236A. Neither compound improved endothelium-dependent vasorelaxation.
In SHR-SP isolated aorta, the vasodilatory responses to the NO-dependent compounds car-
bachol and sodium nitroprusside were attenuated by HSFD. In contrast, the vasodilatory
responses to both GSK2181236A and BAY 60-4552 were unaltered by HSFD, indicating
that reduced NO-bioavailability and not changes in the oxidative state of sGC is respon-
sible for the vascular dysfunction. In summary, GSK2181236A and BAY 60-4552 provide
partial beneﬁt against hypertension-induced end-organ damage. The differential beneﬁcial
effects observed between these compounds could reﬂect tissue-speciﬁc changes in the
oxidative state of sGC andmight help direct the clinical development of these novel classes
of therapeutic agents.
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INTRODUCTION
Nitric oxide (NO), a key endogenous signaling molecule best
known for its robust vasodilator actions (Palmer et al., 1987;
Abbreviations: ANF, atrial natriuretic factor; BNP, brain natriuretic peptide; cGMP,
cyclic guanosine 3′,5′-monophosphate; DMSO, dimethylsulfoxide; HPMC, hydrox-
ylpropyl methylcellulose; HSFD, high salt/fat diet; IM, intramuscular; IP, intraperi-
toneal; I/R, ischemia/reperfusion; KHB, Krebs–Henseleit buffer; L-NAME, Nω-
nitro-L-arginine methyl ester; MALB, microalbumin; MAP, mean arterial pressure;
ND, normal diet; NO, nitric oxide; ODQ, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-
1-one; PBS, phosphate-buffered saline; PKG, protein kinase G; ROS, reactive
Furchgott, 1988), is involved in numerous biological processes
(Pacher et al., 2007). Diminished release of nitric oxide because
of impaired synthesis and/or excessive oxidative degradation
plays an important role in the development of multiple car-
diovascular diseases, including hypertension and heart failure
(Evgenov et al., 2006; Bauersachs and Widder, 2008). As such,
organic nitrates, known as NO-donors, have been utilized as
oxygen species; sGC, soluble guanylate cyclase; SHR-SP, spontaneously hyperten-
sive stroke prone rat; SNP, sodium nitroprusside; SQ, subcutaneous; (P)-VASP,
(phosphorylated) vasodilator-stimulated protein.
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cardiovascular therapeutics for over 140 years (Brunton,1867; Lin-
denfeld et al., 2010). However, long-term nitrate usage is limited
due to tolerance and increased NO scavenging under conditions of
oxidative stress. Indeed, elevated levels of peroxynitrite, produced
by the interaction between NO and superoxide anion, lead to
increased cytotoxicity and can thus exacerbate disease progression
(Pacher et al., 2007).
Soluble guanylate cyclase (sGC) is the primaryNO receptor and
mediates the formation of cyclic guanosine 3′,5′-monophosphate
(cGMP), the secondary messenger compulsory for the vasodila-
tory response to NO. Small molecule drugs directly targeting
sGC are currently being investigated as an alternative approach to
nitrate therapy for increasing cGMP levels (Evgenov et al., 2006).
Twonovel groups of smallmolecule compoundswhich increase
the enzymatic activity of sGC have been identiﬁed over the past
two decades, sGC “stimulators” and “activators” (Ko et al., 1994;
Stasch et al., 2002b). The effectiveness of these compounds differs
depending on the oxidation state of sGC. sGC is a heterodimeric
heme-containing enzyme, consisting of α- and β-subunits. Like
the endogenous ligand NO, sGC stimulators, including YC-1, BAY
41-2272,BAY41-8543,BAY60-4552, andBAY63-2521 (riociguat),
increase sGCactivity onlywhen theheme iron is in its reduced state
(Fe2+; Ko et al., 1994; Stasch et al., 2002a; Evgenov et al., 2006).
These compounds work synergistically with NO and are therefore
considered “NO sensitizers.” Conversely, sGC activators, includ-
ing BAY 58-2667 (cinaciguat), S3448, and HMR1766 (ataciguat),
increase the activity of the enzyme only when the heme iron is
oxidized (Fe3+) or the heme group is missing (Stasch et al., 2002b;
Schindler et al., 2006). The effects of sGC activators are additive
to NO.
Oxidative stress, a risk factor associated with various cardio-
vascular diseases including hypertension, atherosclerosis, diabetes,
and heart failure, can result in oxidation and subsequent loss of
the sGC heme, rendering the enzyme insensitive to either endoge-
nous/exogenous NO or sGC stimulators (Mitrovic et al., 2011). As
sGC activators preferentially bind to the enzyme in its oxidized or
heme-free state, it has been proposed that this class of compounds
might be advantageous in disease states associated with oxidative
stress (Evgenov et al., 2006; Stasch et al., 2006). In support of this
hypothesis, the in vitro vasodilatory effects of the sGC activator
cinaciguat (but not the NO donor glycerol trinitrate) were poten-
tiated under numerous pathological conditions associated with
oxidative stress including atherosclerosis, hypertension, and type
2 diabetes (Stasch et al., 2006).
Although sGC activators are expected to be advantageous over
sGC stimulators in disease states associated with oxidative stress,
to our knowledge, this hypothesis has never been comprehensively
tested in vivo. As such, in the present study,we compared the in vivo
effects of the sGC stimulator BAY 60-4552 (Mitrovic et al., 2009)
with a newly identiﬁed sGC activator, GSK2181236A (Figure 1)
on cardiovascular physiology. Focus was placed on acute and
chronic models of cardiovascular disease associated with oxida-
tive stress: (1) acute coronary artery ischemia/reperfusion (I/R)
in normotensive rats and (2) chronic high salt/fat diet (HSFD) in
spontaneously hypertensive stroke prone rats (SHR-SP). Whereas
neither compound attenuated cardiac I/R injury, both com-
pounds improved survival and provided partial protection against
FIGURE 1 | Structure of the novel sGC activator GSK2181236A
(1-(6-{2-[({3-methyl-4′-[(trifluoromethyl)oxy]-4-biphenylyl}methyl)oxy]
phenyl}-2-pyridinyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid).
chronicHSFD-induced end-organdamage. Interestingly,however,
only sGC activation attenuated cardiac hypertrophy in a blood
pressure-independent manner. In addition, in comparison to the
blunted vasodilatory responses to the NO-dependent vasodila-
tors carbachol and sodium nitroprusside (SNP), the vasodilatory
effects of both the sGC stimulator and activator were not altered
by chronic HSFD in SHR-SP. Overall, these results do not support
the hypothesis that activation of NO-insensitive sGC provides a
greater beneﬁcial effect on cardiovascular hemodynamics, includ-
ing blood pressure, heart rate, vascular resistance, and end-organ
damage, than does NO-sensitive sGC stimulation, but suggest
that sGC activation might be advantageous over sGC stimulation
for mitigating cardiac hypertrophy associated with cardiovascular
disease.
MATERIALS AND METHODS
All animal studies were performed in Association for Assessment
and Accreditation of Laboratory Animal Care-accredited facilities
in accordance with the Guide for Care and Use of Laboratory
Animals (NIH Publication 85-23). Experimental protocols were
reviewed and approved by the respective InstitutionalAnimal Care
and Use Committee at GlaxoSmithKline and CV Dynamics, Inc.
(Newark, NJ, USA).
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PHOSPHORYLATION OF VASODILATOR-STIMULATED
PHOSPHOPROTEIN
The potency, efﬁcacy, and mechanism of action of the sGC mod-
ulators GSK2181236A and BAY 60-4552 were assessed by mea-
suring phosphorylation of the protein kinase G (PKG) substrate
vasodilator-stimulator protein (VASP) in rat aortic smooth mus-
cle cells. Brieﬂy, in 96-well tissue culture test plates (Techno Plastic
Products, Trasadingen, Switzerland), primary rat aortic smooth
muscle cells were incubated at 37˚C for 10min in the presence
or absence of 10μM 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-
one (ODQ), a highly selective, and irreversible sGC heme iron
oxidant.Dimethylsulfoxide (DMSO)vehicle or varying concentra-
tions of GSK2181236A (2 pM to 1μM) or BAY 60-4552 (15 nM to
100μM) were then added. Following a 30min incubation at 37˚C,
media was aspirated and the cells were rinsed with phosphate-
buffered saline (PBS) and ﬁxed with 4% formaldehyde in PBS
by incubating at room temperature for 20min. Cells were then
washed with PBS and permeabilized for 10min using 0.1% tri-
ton X-100 in PBS. Following PBS rinsing, the cells were blocked
for 90min at room temperature with Odyssey Blocking Buffer (LI-
COR,Cambridge,UK). The buffer was aspirated and the cells were
treated overnight at 4˚C with primary antibody [(pSer239) VASP,
rabbit polyclonal Ab, Cell Signaling Technology, Danvers, MA,
USA] diluted 1:500 in Odyssey Blocking Buffer. Following three
washes with 0.05% Tween 20, the cells were treated for 1 h at room
temperature with secondary antibody (IRDye® 800CW Donkey
Anti-Rabbit IgG, LI-COR) diluted 1:2500 in Odyssey Blocking
Buffer with 0.05% Tween 20. Following two washes with PBS,
infrared ﬂuorescence was measured using an Odyssey Infrared
Imaging System (LI-COR).
IN VITRO SELECTIVITY PROFILE OF GSK2181236A
The secondary pharmacological proﬁle (i.e., sGC-independent
activity) of GSK2181236A was assessed in cell-based functional
assays by characterizing the interaction between GSK2181236A
and 38 distinct human enzymes, ion channels, transporters, and
G-protein-coupled receptors including 5-HT (5-HT1B/2A/2C/3), 5-
HT transporter (SERT), adenosine (A2a), adrenergic (α1B/2C, β2),
Aurora B kinase, cycoloxygenase-2 (COX-2), CaV1.2, cytochrome
P450 (CYP2C19, 2D6, and 3A4), dopamine (D2), dopamine
transporter (DAT), gamma-aminobutyric acid (GABAA), glyco-
gen synthase kinase-3 (GSK3β) histamine (H1), KV1.5, KV7.1,
KV11.1, lymphocyte-speciﬁc protein tyrosine kinase (LCK), l-
monoamine oxidase (MAO-B) muscarinic (M1/2), NaV1.5, nico-
tinic (α1 nAChR),noradrenaline transporter (NET), opioid (κ,μ),
organic anion transporting polypeptide C (OATP1B1), phospho-
diesterase 5 (PDE5), phosphatidylinositol 3-kinase (PI3Kγ), preg-
nane X receptor (PXR), tachykinin (NK1), and vasopressin (V1a).
HEMODYNAMIC ASSESSMENT OF GSK2181236A AND BAY 60-4552 IN
SPRAGUE DAWLEY RATS
To identify equi-efﬁcacious doses of GSK2181236A and BAY 60-
4552, heart rate and blood pressure were monitored in male
Sprague Dawley (SD) rats (∼500g, n = 4–6 per group) via sur-
gically implanted radiotelemetry transmitters (PhysioTel PA-C40,
Data Sciences International, St. Paul, MN, USA). Following oral
gavagedosing (0.03–3.0mg/kg),hemodynamicdatawere recorded
every 5min for 10 s and then averaged every hour. Since both
compoundsdemonstrated transient effects onheart rate andblood
pressure, data are presented as an average change from vehicle over
an 11 h period post-dose.
MYOCARDIAL I/R INJURY AND HEMODYNAMIC ASSESSMENT OF
GSK2181236A AND BAY 60-4552 IN SD RATS
This study was performed at CV Dynamics, Inc. (Newark, NJ,
USA). Male SD rats were obtained from Charles River Labora-
tories, Inc. (Kingston, NY, USA). At 2months of age, rats were
pre-medicated with atropine (0.04mg/kg IM) then anesthetized
with a loading dose of pentobarbital sodium (65mg/kg IP). A
supplemental dose of pentobarbital sodium (16.3mg/kg IP) was
administered 30–40min after the initial anesthesia. Marcaine
(0.025–0.05mg/rat IM) was administered locally for pain con-
trol, and anesthetized rats were subjected to a thoracotomy at the
fourth intercostal space. The left descending coronary artery was
occluded using a 5-0 silk snare for 30min, followed by reperfusion
for 24 h. The coronary occlusion and reperfusion were veriﬁed
by visual inspection (color change of myocardium from pale to
pink) and by EKG monitoring [ST elevation and widening of the
QRS; Gould BioTACH ECG module (Valley View, OH, USA) with
a Tektronix TDS 220 monitor (Beaverton, OR, USA)]. A 2% lido-
caine solution (2–3mg/kg) was dripped directly onto the heart as
needed for arrhythmia control during ischemia, and procainamide
(12.5mg/kg IP) was administered 15min prior to reperfusion.
Rats were orally gavagedwith vehicle (0.5%HPMC,5%DMSO,
and 0.1% Tween 80; 10mL/kg; n = 14), GSK2181236A (0.1 or
1.0mg/kg; n = 11–14), or BAY 60-4552 (0.3 or 3.0mg/kg; n = 10–
12) 2 h prior to ischemia. Blood was collected at the initiation
of ischemia and after 24 h reperfusion. Plasma was obtained for
analysis of compound concentrations and levels of cardiac Tro-
ponin I (cTnI), a circulating biomarker of cardiac injury. Plasma
concentrations of cTnI were determined using a commercially
available ELISA (catalog #2010-2-HSP, Life Diagnostics, West
Chester, PA, USA) according to the manufacturer’s instructions.
Plasma compoundconcentrationsweredeterminedbyLC/MS/MS
(API 5000 triple quadrupole mass spectrometer, ABSciex, Fos-
ter City, CA, USA; Prominence liquid chromatographic system,
Shimadzu, Columbia, MD, USA). Rats were anesthetized with a
mixture of ketamine and xylazine (35 and 5mg/kg, IM) and euth-
anized via exsanguination. Hearts were excised and perfused with
1% Evans blue dye in saline then perfused-ﬁxed with 10% neutral
buffered formalin (∼90mmHg perfusion pressure). Hearts were
sliced on the short axis from apex to base at 1–2mm intervals, and
the ischemic area (area at risk) was evaluated using Image Pro-Plus
(Media Cybernetics, Inc., Bethesda, MD, USA). Fresh heart slices
were stained with 1% triphenyltetrazolium and evaluated using
Image Pro-Plus for determination of infarct size.
CARDIAC AND RENAL FUNCTION ASSESSMENT OF GSK2181236A AND
BAY 60-4552 IN HSFD FED SHR-SP
The SHR-SP is an established model of genetic hypertension.
Exposure to a HSFD exacerbates endothelial dysfunction, systemic
vascular resistance and hypertension, and accelerates end-organ
damage (Ma et al., 2001). Decreases in endothelium-dependent
vasorelaxation in this model have been associated with reduced
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levels of NO bioactivity and increased generation of superoxide
and/or peroxynitrite anions (McIntyre et al., 1997, 1999;Kerr et al.,
1999;Ma et al., 2001; see Bauersachs andWidder, 2008 for review).
As such, a cohort of HSFD SHR-SP was established as a model of
cardiovascular disease associated with chronic oxidative stress in
this study.
Male SHR-SPs (n = 75) were obtained from Charles River
Laboratories, Inc. (Kingston, NY, USA) and maintained on
a normal powdered rodent diet (Lab Diet 5001, PMI Nutri-
tion International, LLC, St. Louis, MO, USA) and tap water
ad libitum. A subgroup of animals (n = 45) was anesthetized
with isoﬂurane and surgically implanted with radiotelemetry
transmitters (PhysioTel PA-C40, Data Sciences International,
St. Paul, MN, USA). The transmitter catheter was threaded
through the femoral artery into the abdominal aorta. At 11–
12weeks of age, baseline blood pressure and heart rate were
measured for 5 days (10 s recordings every 5min) in normal
caging, then rats were acclimated to metabolic caging for a
minimum of 48 h before a basal 24 h urine sample and blood
were collected. After baseline measures, rats were assigned to six
groups (n = 8–14 per group) according to mean arterial pres-
sure (MAP; telemetered rats only) and body weight: normal
diet (ND) control, HSFD, HSFD+ 0.1mg/kg/day GSK2181236A,
HSFD+ 1.0mg/kg/day GSK2181236A, HSFD+ 0.3mg/kg/day
BAY 60-4552, and HSFD+ 3.0mg/kg/day BAY 60-4552. The ND
group was maintained on normal chow and water throughout
the study. The other groups received a fat-enriched rodent diet
(24.5% fat, Zeigler Bros., Inc., Gardners, PA, USA) and a 1%
NaCl drinking water solution ad libitum for 8 week (Willette et al.,
2009). Rats displaying signs of morbidity which included pilo-
erection, lack of grooming, persistent body weight loss, lethargy,
or seizure/convulsions, were promptly euthanized.
Treatments were administered in respective diets starting
1week after the initiation of HSFD. Urine collections were
repeated on weeks 2, 4, 6, and 8 and blood was sampled in the
morning after each 24 h collection period for assessment of renal
function. Plasma creatinine and urine sodium, microalbumin
(MALB), and creatinine were ascertained using an AU640 Chem-
istry Analyzer (Olympus America, Inc., Center Valley, PA, USA).
Plasma compound concentrations were determined as described
above.
During week 7, cardiac function and morphometry were eval-
uated via transthoracic echocardiography. Rats were anesthetized
with isoﬂurane (2–4% induction and 1–3% maintenance). Two-
dimensional gray scale images of the left ventricle were obtained
in the short axis plane at mid-ventricle level and in the parasternal
long axis plane using a GE Vivid 7 system (GE Medical Systems,
Milwaukee, WI, USA) and stored as digital cineloops. Pulse wave
Doppler recordings from the LV outﬂow were obtained to deter-
mine heart rate. All images were analyzed by a single observer
using a GE EchoPac (GE Medical Systems, Milwaukee, WI, USA).
LV volumes were calculated as V = 56 (LVA × LVL) where LVA is
area of LV chamber from the short axis view and LVL is the LV
length from the long axis view at end diastole and end systole.
LV mass was calculated from two dimensional images using the
area-length method (Lang et al., 2005). Analysis was performed
on three to ﬁve cardiac cycles.
On week 8, isoﬂurane anesthetized rats were euthanized via
exsanguination. The thoracic aorta was excised for assessment
of endothelial function as described below. Hearts were snap-
frozen in liquid nitrogen and stored at −80˚C for later analysis
of gene expression changes associated with cardiac hypertrophy
and ﬁbrosis (see below for procedure details).
GENE EXPRESSION ANALYSIS OF CARDIAC TISSUE
Cardiac gene expression was analyzed following chronic (7 week)
BAY60-4552orGSK2181236A treatment inHSFDSHR-SP.Hearts
were homogenized in Trizol and RNA was extracted using the
RNeasy Plus Mini kit protocol (Qiagen, Valencia, CA, USA) with
a 40μL elution volume. RNA was quantiﬁed using a Nanodrop
Spectrophotometer ND-1000 (Thermo Fisher Scientiﬁc, Wilm-
ington,DE,USA) and converted to cDNA using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad,
CA, USA). Taqman assays were performed using a 384-well plate
format with individual primer-probes and Taqman Universal PCR
Master Mix (Applied Biosystems) and run on the 7900 HT Fast
Real-Time PCR System (Applied Biosystems). SDS 2.3 software
(Applied Biosystems) was used to obtain raw C t values with man-
ual threshold set at 0.10. Array Studio software (version 3.6.2;
OmicSoft Corporation, Cary, NC, USA) was used to normalize
gene expression data, by analysis of covariance, to the housekeeper
genes β-2-microglobulin (B2m) and peptidyl-prolyl cis-trans iso-
merase A (Ppia). No outliers were detected by means of principal
component analysis.
The following genes were analyzed: α-skeletal actin (Acta1),
type 1 collagen-alpha 1 (Col1a1), type 3 collagen-alpha 1 (Col3a1),
connective tissue growth factor (CTGF; Ctgf), matrix metallopro-
teinase 2 (MMP2; Mmp2), matrix metalloproteinase 9 (MMP9;
Mmp9), α-myosin heavy chain (α-MHC; Myh6), β-myosin heavy
chain (β-MHC; Myh7 ); atrial natriuretic factor (ANF; Nppa),
brain-type natriuretic peptide (BNP; Nppb), cGMP-speciﬁc phos-
phodiesterase 5A (PDE5A; Pde5a), type 2 cGMP-dependent pro-
tein kinase (PKG2; Prkg2), and transforming growth factor beta 1
(TGF-β1; Tgfb1).
ISOLATED ARTERY VASODILATATION
Male Wistar Kyoto (WKY; Charles River Laboratories, Inc.,
Raleigh, NC, USA) were anesthetized with inhaled isoﬂurane
(5% in O2) and euthanized by exsanguination. Thoracic aorta
was isolated, cleaned of adherent tissue, cut into 3mm rings,
and suspended in 10mL organ baths containing Krebs–Henseleit
buffer (KHB) of the following composition (mM): NaCl, 112.0;
KCl, 4.7; KH2PO4, 1.2; MgSO4, 1.2; CaCl2, 2.5; NaHCO3, 25.0;
glucose, 11.0. KHB was maintained at 37˚C and aerated with
95%O2:5%CO2 (pH 7.4). Changes in isometric force were mea-
sured under 1g optimal resting tension using MLT0201/D force-
displacement transducers (Letica, Barcelona, Spain) and recorded
digitally (Chart 5.0 software, ADInstruments, Colorado Springs,
CO, USA). After a 1 h equilibration period, each tissue was con-
tracted to equilibrium with 60mM KCl, washed with KHB and
allowed to relax to the resting tension. The 60mM KCl con-
traction was repeated and subsequent contractile responses were
normalized to this second KCl response. Each tissue was then con-
tracted to equilibration with 1 μM phenylephrine, washed with
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KHB and allowed to relax to the resting tension. In order to
further investigate the mechanism by which BAY 60-4552 and
GSK2181236A were modulating sGC function, the vasodilatory
effects of both compounds were assessed in the presence and
absence of ODQ, a heme-site inhibitor of sGC. Following a 20min
pre-treatment with DMSO vehicle (0.1% ﬁnal concentration, v/v)
or ODQ (10μM), aortae were contracted with 0.3μM phenyle-
phrine (an approximate EC80 concentration). Once the contractile
response to phenylephrine reached a plateau (∼10min), contrac-
tile tone was reversed by adding cumulative concentrations of BAY
60-4552 or GSK2181236A to the tissue baths at log increments
(0.1 nM to 10μM).
In separate studies, endothelial function was assessed follow-
ing chronic (7 week) BAY 60-4552 or GSK2181236A treatment in
SHR-SP on HSFD. SHR-SP fed either normal or HSFD served
as controls. Rats were anesthetized and thoracic aorta were iso-
lated and treated with KCl and phenylephrine as described above.
Cumulative concentration-response curves to phenylephrine were
obtained by adding 0.5 log unit increments (1 nM to 3μM). Fol-
lowing several washes with KHB, each vessel was contracted to
equilibrium with 0.3μM phenylephrine and tone was reversed
by adding cumulative amounts of carbachol at 0.5 log unit inter-
vals (10 nM to 30μM). Following several KHB washes, the tissues
were again contracted to equilibrium with 0.3μM phenylephrine
and tone was reversed by adding cumulative amounts of SNP at
0.5 log unit intervals (0.1 nM to 3μM). In separate tissues from
both the normal and HSFD SHR-SP control groups, the direct
vasodilatory effects of BAY60-4552 andGSK2181236Awere inves-
tigated. Contractile tone induced by 0.3 μM phenylephrine was
reversed by adding cumulative concentrations of BAY 60-4552
or GSK2181236A to the tissue baths at log increments (0.1 nM
to 10μM).
MATERIALS
BAY 60-4552 and GSK2181236A were synthesized by Glaxo-
SmithKline (King of Prussia, PA, USA). DMSO and ODQ were
from EMD Chemicals (Gibbstown, NJ, USA), phenylephrine, car-
bachol, SNP,HPMC,Tween 80,Evan’s blue dye, and triphenyltetra-
zolium dye were from Sigma (St Louis, MO, USA) and isoﬂurane
was from Abbott Laboratories (North Chicago, IL,USA). All med-
ications administered to animals during survival and non-survival
procedures were of pharmaceutical grade. All other reagents were
of analytical grade.
DATA ANALYSIS
Data are presented as mean± SEM unless indicated other-
wise. For analysis of physiologic and contractility data, sta-
tistical comparisons were made using two-tailed t -tests, or
one- or two-way ANOVA analysis with a Dunnett’s or Bonfer-
roni’s post-test, respectively, where ∗P < 0.05, ∗∗P < 0.01, and
∗∗∗P < 0.001. For gene expression analysis, fold changes and
statistical signiﬁcance were determined by performing one-
way ANOVA with False Discovery Rate – Benjamini and
Hochberg (FDR-BH) multiplicity where ∗P < 0.05, ∗∗P < 0.01,
and ∗∗∗P < 0.001. Concentration-dependent P-VASP formation,
vasoconstriction and vasodilation curves were ﬁt by non-linear
regression (Graphpad Prism 5.0, La Jolla, CA, USA). In cases
where non-linear regression analysis could not be accurately per-
formed due to the lack of complete concentration-response curves
(e.g., vasodilatory responses in the presence of ODQ), individ-
ual responses to each concentration of vasodilator were com-
pared. Survival curves were generated using the Kaplan–Meier
method and each curve was individually compared to HSFD
control SHR-SP using the Mantel–Cox log-rank test (Graph-
Pad Prism 5.0) where statistical difference was designated as
P < 0.05.
RESULTS
EFFECTS OF ODQ ON GSK2181236A- AND BAY 60-4552-MEDIATED
P-VASP FORMATION AND VASODILATION
GSK2181236A increased P-VASP levels in a concentration-
dependent manner with an EC50 of 12.7 nM (Figure 2A; Table 1).
This value is consistent with primary cell-free rat and human
sGC enzyme assays where GSK2181236A increased sGC activ-
ity (cGMP formation) with EC50s of 27 and 25 nM, respectively
(not shown). Pre-treatment with the heme-site sGC inhibitor
ODQ (10μM) potentiated the effects of GSK2181236A, causing
a 4.7-fold leftward-shift to the concentration-response curve and
augmenting the P-VASP maximal response by 32% (Figure 2A;
Table 1). The NO-sensitive sGC stimulator BAY 60-4552 also
increased P-VASP levels in a concentration-dependent manner.
However, in contrast to GSK2181236A, ODQ attenuated BAY
60-4552-inducedP-VASP formation, causing a 9.8-fold rightward-
shift to the BAY 60-4552 concentration-response curve and a trend
toward suppressing the maximal response by 7% (Figure 2B;
Table 1).
Consistent with the P-VASP assay results, ODQ augmented
the vasodilatory effects of the sGC activator GSK2181236A.
Speciﬁcally, ODQ increased the vasodilatory responses to 0.1,
1, and 10μM GSK2181236A by 41, 36, and 21%, respectively
(Figure 2C). In contrast to GSK2181236A, the vasodilatory
response to the sGC stimulator BAY 60-4552 was attenuated by
ODQ treatment (ODQ reduced responses to 0.1 and 1μM BAY
60-4552 by 48 and 30%, respectively; Figure 2D). These results
conﬁrm the mechanism of action proposed for BAY 60-4552
(NO-sensitive sGC stimulation; Mitrovic et al., 2009) and indi-
cate that GSK2181236A increases sGC enzymatic activity in a
NO-insensitive manner. In addition, these results support the
hypothesis that activation of NO-insensitive sGC, but not stim-
ulation of NO-sensitive sGC, will be potentiated under conditions
of oxidative stress.
IN VITRO SELECTIVITY PROFILE OF GSK2181236A
The most potent interaction between GSK2181236A and a
“non-sGC” protein occurred with OATP1B1, where the com-
pound inhibited the transporter activity of this protein with
an IC50 of 0.3μM. Interactions (EC50s or IC50s) of ≥2.5μM
were observed at all other proteins tested. As such, consid-
ering GSK2181236A activates sGC with an EC50 of 12.7 nM
(P-VASP formation; Table 1), GSK2181236A functioned as
a selective sGC activator with 23-fold selectivity for sGC
over OATP1B1 and ≥197-fold selectivity for all other tested
proteins.
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FIGURE 2 | Effects of the sGC heme-site inhibitor ODQ on
GSK2181236A- and BAY 60-4552-mediated P-VASP formation and
vasodilation. (A) GSK2181236A increased P-VASP levels in a
concentration-dependent manner in rat aortic smooth muscle cells and
these effects were potentiated by pre-treatment with 10μM ODQ. (B)
BAY 60-4552 increased P-VASP formation, but, in contrast to
GSK2181236A, the concentration-dependent effects of BAY 60-4552 were
attenuated by ODQ. P-VASP data are representative from one experiment
performed in triplicate and are expressed as mean±SEM (consolidated
pEC50 and Emax values and statistical comparisons are provided inTable 1).
Consistent with the P-VASP assay results, ODQ (C) augmented the
vasodilatory effects of the sGC activator GSK2181236A inWKY rat isolated
aorta and (D) attenuated the vasodilatory effects of BAY 60-4552.
Vasodilatory data are expressed as mean±SEM of 6–10 animals.
Non-linear regression analysis of several vasodilation
concentration-response curves in the presence of ODQ could not be
accurately performed due to the lack of a complete sigmoidal response;
therefore, statistical comparisons of vehicle vs. ODQ were made at each
concentration of vasodilator using two-way ANOVA analysis with a
Bonferroni’s post-test where *P <0.05, **P <0.01, and ***P <0.001.
Table 1 | Effects of GSK2181236A or BAY 60-4552 on P-VASP formation
in rat aortic smooth muscle cells.
EC50 (nM) Emax (% DMSO)
Control ODQ (10μM) Control ODQ (10μM)
GSK2181236A 12.7±4.7 2.7±0.6** 379±26 502±26*
BAY 60-4552 353±89 3,264±737*** 388±39 362±24
All values are expressed as mean±SEM (n=4 independent experiments per-
formed in at least duplicate). Emax values are expressed as relative ﬂuores-
cence units normalized to DMSO vehicle. Statistical comparisons of vehicle-
and ODQ-treated cells were performed using two-tailed t-tests where *P<0.05,
**P<0.01, and ***P<0.001 vs. vehicle control.
IDENTIFICATION OF EQUI-EFFICACIOUS DOSES OF GSK2181236A AND
BAY 60-4552 IN SD RATS
The sGC activator GSK2181236A increased heart rate and reduced
blood pressure at doses ≥0.3mg/kg (Figure 3). The sGC stimu-
lator BAY 60-4552 was approximately threefold less potent than
GSK2181236A (Figure 3). Doses for the I/R and HSFD SHR-SP
studies were selected based upon the highest no-effect dose
(0.1mg/kg GSK2181236A and 0.3mg/kg BAY 60-4552) and a dose
10-fold higher which signiﬁcantly changed heart rate and mean
blood pressure (1mg/kgGSK2181236A and 3mg/kgBAY60-4552;
Figure 3).
EFFECTS OF GSK2181236A AND BAY 60-4552 ON I/R INJURY IN SD RATS
Cardiac I/R resulted in an infarct size/area at risk of 46.7± 3.5%
(Figure 4A) and plasma cTnI levels of 6.4± 0.7 ng/mL in
vehicle-treated rats (Figure 4B). Neither GSK2181236A (0.1 and
1.0mg/kg) nor BAY 60-4552 (0.3 and 3mg/kg) signiﬁcantly
altered either endpoint (Figure 4), suggesting that activation
of NO-insensitive sGC does not provide an advantage over
stimulation of NO-sensitive sGC with regard to protecting the
myocardium from ischemic injury. Plasma concentrations of
GSK2181236A and BAY 60-4552 were consistent with levels
observed in the SD hemodynamic study (data not shown). Mor-
tality rates were similar between all groups: sham, 0 of 4; vehicle,
1 of 15 (due to anesthesia); 0.1mg/kg GSK2181236A, 1 of 15 (due
to anesthesia), 1mg/kg GSK2181236A, 2 of 13 (due to arrhyth-
mia during occlusion and unknown cause during reperfusion);
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FIGURE 3 | Effect of GSK2181236A and BAY 60-4552 on (A) heart rate and
(B) mean arterial pressure (MAP) in normotensive Sprague Dawley rats.
A single p.o. dose of compounds in radio telemetered rats resulted in a
dose-dependent change in heart rate and blood pressure. Data are presented
as an average change from vehicle over an 11 h period post-dose. All data are
mean±SEM of four to six animals. Statistical comparisons to vehicle were
performed for each dose using one-way ANOVA with a Dunnett’s post-test
where *P <0.05, **P <0.01, and ***P <0.001.
A B
FIGURE 4 | Effect of GSK2181236A and BAY 60-4552 on cardiac
ischemia/reperfusion injury in Sprague Dawley rats (n =10–14 per
group). Acute p.o. administration of compounds did not signiﬁcantly alter (A)
infarct size as a percentage of the area at risk or (B) circulating levels of
cardiac troponin I (cTnI), an indicator of cardiac injury. Data are presented as
mean±SEM. Statistical comparisons to vehicle were performed using
one-way ANOVA with a Dunnett’s post-test where signiﬁcance was
determined as P <0.05.
0.3mg/kg BAY 60-4552, 2 of 12 (due to arrhythmia and trauma
during occlusion); 3mg/kg BAY 60-4552, 2 of 14 (due to cardiac
puncture and trauma).
EFFECTS OF GSK2181236A AND BAY 60-4552 ON BLOOD PRESSURE,
RENAL AND CARDIAC FUNCTION, AND SURVIVAL IN SHR-SP
Chronic dietary administration of GSK2181236A and BAY 60-
4552 sustained dose-linear plasma concentrations that were con-
sistent with levels observed previously in the SD hemodynamic
and I/R studies (data not shown).
Whereas the survival rate of the ND SHR-SPs was 100%, 8week
of HSFD treatment reduced survival to only 14% (P < 0.001
vs. ND; Figure 5A). Treatment for 7week with 0.1mg/kg/day
GSK2181236A did not improve survival; however, the higher dose
(1.0mg/kg/day) increased the survival rate to 69% (P < 0.01 vs.
HSFD;Figure 5A). In contrast, both the 0.3 and 3mg/kg/day doses
of BAY 60-4552 improved survival (46 and 69%, P < 0.01, and
P < 0.05 vs. HSFD, respectively; Figure 5A).
In the ND group, MAP averaged 142± 4mmHg at the start of
study and increased to 153± 2mmHg after 8 week (Figure 5B).
In contrast to ND, the MAP in SHR-SPs fed a HSFD for
8week increased from 140± 2 to 192± 10mmHg (P > 0.05
and P < 0.01 vs. ND, respectively; Figure 5B). Compared to
the HSFD controls, treatment for 7week with GSK2181236A
(1.0mg/kg/day) mildly, but not signiﬁcantly, reduced MAP by
9 to 183± 7mmHg (P > 0.05; Figure 5B). Seven weeks of
BAY 60-5442 (3mg/kg/day) reduced MAP to a greater extent
than 1.0mg/kg/day GSK2181236A, reducing MAP by 17 to
175± 1mmHg (P > 0.05; Figure 5B). The lower doses of both
compounds (0.1mg/kg/day GSK2181236A and 0.3mg/kg/day
BAY 60-4552) did not have any effect on MAP compared to the
HSFD controls (Figure 5B).
Urine output in the ND group was 10± 1mL/day under
basal conditions and 14± 1mL/day at 8 week (P < 0.01 vs. base-
line; Figure 6A). Similarly, MALB excretion was 1.3 ± 0.2mg/day
at baseline and 5.3± 0.8mg/day after 8 week (P < 0.001 vs.
baseline; Figure 6B), and sodium excretion was 2.3± 0.2 and
2.8± 0.1mmol/day at baseline and 8week, respectively (P < 0.05
vs. baseline; Figure 6C). Eight weeks of HSFD increased urine
output in SHR-SPs from 15± 4 to 111± 21mL/day (P > 0.05
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FIGURE 5 | Chronic administration of GSK2181236A and BAY
60-4552 enhanced (A) survival and similarly, but not significantly,
reduced (B) blood pressure in age-matched, radiotelemetered HSFD
SHR-SPs.Treatments (T) were administered in chow starting 1week
after the initiation of HSFD. Average daily blood pressure measurements
(10 s recordings measured every 5min for 24 h) are reported for
2 days/week for the duration of the study. Blood pressure data were
analyzed using two-way ANOVA analysis with a Bonferroni’s post-test
and statistical comparisons were made to HSFD control (**P <0.01;
data are presented as mean±SEM of two to eight animals per group per
time point). Survival curves were generated using the Kaplan–Meier
method. Each curve was individually compared to HSFD SHR-SP using
the Mantel–Cox log-rank test where ***P <0.001, **P <0.01, and
*P <0.05.
and P < 0.001 vs. ND, respectively; Figure 6A), increased MALB
excretion from 1.3 ± 0.03 to 282.4± 20.2mg/day (P > 0.05 and
P < 0.001 vs. ND, respectively; Figure 6B), and increased sodium
excretion from 2.4 ± 0.4 to 26.4± 2.2mmol/day (P > 0.05 and
P < 0.001 vs. ND, respectively; Figure 6C). Compared to the
HSFD controls, GSK2181236A (0.1 and 1.0mg/kg/day) did
not alter urine output, MALB excretion, or sodium excretion
(Figures 6A–C). Seven weeks of treatment with BAY 60-4552
(0.3 and 3.0mg/kg/day) dose-dependently decreased urine output
to 79± 11 and 56± 10mL/day (P < 0.05 vs. HSFD; Figure 6A).
BAY 60-4552 (3.0mg/kg/day) also reduced MALB excretion
to 142± 42mg/day and sodium excretion to 16± 2mmol/day
(P < 0.05 vs. ND; Figures 6B,C). Glomerular ﬁltration rates esti-
mated by creatinine clearance were similar in ND and HSFD
SHR-SPs at baseline and at the end of study (P > 0.05 vs. ND), and
were not altered by treatment with GSK2181236A or BAY 60-4552
(P > 0.05 vs. HSFD; Figure 6D). Overall, these data suggest that
stimulation of NO-sensitive sGC delays development of renal dys-
function more effectively than activation of NO-insensitive sGC.
However, it should be noted that the renal protection afforded by
BAY60-4552might be a direct result of blood pressuremodulation
(BAY 60-4552 reduced blood pressure to a greater extent than
GSK2181236A; see above).
Upon echocardiographic analysis, as compared to ND, HSFD
produced mild LV hypertrophy [LV mass to body weight ratio
(LVM/BW) was increased by 15%; P < 0.05] with preserved ejec-
tion fraction (Table 2). LVM/BW was reduced by treatment with
0.1 and 1.0mg/kg/day GSK2181236A to ND levels (P < 0.05
vs. HSFD; Table 2). BAY 60-4552 (3.0mg/kg/day) similarly, but
not signiﬁcantly, reduced LVM/BW to near ND levels (P > 0.05;
Table 2). No other morphometric or functional parameters
were altered by GSK2181236A or BAY 60-4552 as compared to
HSFD (Table 2). Thus, although both compounds attenuated the
development of cardiac hypertrophy, only activation of sGC by
GSK2181236Adid so in amanner independent of changes in blood
pressure.
EFFECTS OF GSK2181236A AND BAY 60-4552 ON CARDIAC GENE
EXPRESSION IN SHR-SP
Compared to ND SHR-SP, HSFD reduced the cardiac expression
of α-MHCby 1.6-fold (P < 0.01;Figure 7A) and increased expres-
sion of α-skeletal actin by 1.8-fold (P < 0.001; Figure 7B), ANF
by 2.0-fold (P < 0.001; Figure 7C), PDE5A by 1.3-fold (P < 0.05;
Figure 7D), PKG2 by 2.6-fold (P < 0.01; Figure 7E), and TGF-β1
by 1.3-fold (P < 0.01; Figure 7F). Eight weeks of HSFD did not
alter cardiac expression of BNP, CTGF, type 1 collagen-alpha 1,
type 3 collagen-alpha 1, MMP2, or MMP 9 (data not shown).
After 7 weeks of treatment, 1.0mg/kg/day GSK2181236A atten-
uated the HSFD-induced increase of α-skeletal actin and ANF by
1.7- and 1.4-fold, respectively (P < 0.01 and P < 0.05 vs. HSFD,
respectively; Figures 7B,C).
Similarly, 0.3 and 3.0mg/kg/day BAY 60-4552 attenuated the
HSFD-induced increase of α-skeletal actin by 1.3- and 1.4-fold,
respectively (P < 0.05 vs. HSFD; Figure 7B), but only exhib-
ited a non-signiﬁcant trend toward attenuating the increase
of ANF (P > 0.05 vs. HSFD; Figure 7C). Expression of α-
MHC, PDE5A, PKG2, and TGF-β1 was not altered by treatment
with GSK2181236A or BAY 60-4552 (Figures 7A,D–F). Overall,
GSK2181236A and BAY 60-4552 exhibited similar cardioprotec-
tive gene expression proﬁles.
VASODILATORY EFFECTS OF CARBACHOL, SNP, BAY 60-4552, AND
GSK2181236A IN SHR-SP
At the end of study, thoracic aortae were isolated and used to
assess contractile function. Aortae from HSFD SHR-SP exhibited
a reduced maximal relaxation response to the endothelium-
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FIGURE 6 | Chronic administration of BAY 60-4552, but not GSK2181236A
attenuated the increase in (A) urine output, (B) microalbumin excretion,
and (C) sodium excretion in age-matched HSFD SHR-SPs. Neither
compound altered glomerular ﬁltration rate as estimated by (D) creatinine
clearance. Treatments were administered in chow starting 1week after the
initiation of HSFD. Data for moribund animals or animals that died prior to the
end of study were not included. Remaining data were analyzed using
two-way ANOVA analysis with a Bonferroni’s post-test and statistical
comparisons were made to the HSFD control (*P <0.05 and ***P <0.001;
data are presented as mean±SEM of three to nine animals per group).
Table 2 | Effects of chronic GSK2181236A or BAY 60-4552 treatment on echocardiographic parameters in SHR-SP.
HSFD+GSK2181236A HSFD+BAY 60-4552
ND (n =8) HSFD (n =11) 0.1mg/kg/day (n =6) 1.0mg/kg/day (n =10) 0.3mg/kg/day (n =9) 3.0mg/kg/day (n =10)
BW (g) 332±3 315±7 331±16 338±5 328±6 345±14
EDV (μL) 39±16 330±15 331±29 332±22 356±21 379±21
ESV (μL) 141±10* 102±7 110±11 98±10 111±11 120±9
EF (%) 65±1 69±1 67±2 71±1 69±2 67±1
SV (μL) 255±9 229±10 222±19 234±14 245±14 259±13
CO (mL/min) 89±4 80±4 76±7 80±5 86±6 89±6
LVM/BW (mg/g) 2.68±0.03* 3.08±0.06 2.69±0.08* 2.82±0.07* 3.06±0.07 2.85±0.10
Echocardiographic analysis was performed after 7weeks of HSFD. Treatments were administered in chow starting 1week after initiation of HSFD. All values are
expressed as mean±SEM. ND, normal diet; HSFD, high salt/fat diet; BW, body weight at week 7; EDV, end diastolic volume; ESV, end systolic volume; EF, ejection
fraction; SV, stroke volume; CO, cardiac output; LVM/BW, left ventricular mass to body weight ratio. Statistical comparisons were performed using one-way ANOVA
analysis with a Dunnett’s post-test where *P<0.05 vs. HSFD control SHR-SP.
dependent vasodilator carbachol as compared to tissues from ND
SHR-SP (Table 3; Figure 8A). In addition, the relaxation response
to the endothelium-independent vasodilator and NO-donor SNP
was right-shifted in HSFD SHR-SP (Table 3; Figure 8B). Chronic
treatment with GSK2181236A (0.1 and 1mg/kg/day) or BAY 60-
4552 (0.3 and 3mg/kg/day) failed to signiﬁcantly restore the
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FIGURE 7 | Effect of GSK2181236A and BAY 60-4552 on cardiac mRNA
expression following 8weeks of HSFD in SHR-SPs. HSFD reduced the
myocardial expression of (A) α-myosin heavy chain (α-MHC; Myh6 ), an
indicator of reduced cardiac contractility, and increased the expression of the
pathological hypertrophy and ﬁbrosis gene markers (B) α-skeletal actin (Acta1),
(C) atrial natriuretic factor (ANF; Nppa), (D) cGMP-speciﬁc phosphodiesterase
5A (PDE5A; Pde5a), (E) type 2 cGMP-dependent protein kinase (PKG2;
Prkg2), and (F) transforming growth factor beta 1 (TGF-β1;Tgfb1). Treatments
were begun 1week after initiation of HSFD and attenuated the HSFD-induced
increases of (B) α-skeletal actin and (C) ANF expression to near normal diet
(ND) levels. Gene expression data were normalized to levels of transcript
encoding β-2-microglobulin (B2m) and peptidyl-prolyl cis-trans isomerase A
(Ppia). All data are mean±SEM of four to nine animals. Statistical
comparisons were performed using one-way ANOVA, with False Discovery
Rate – Benjamini and Hochberg (FDR-BH) multiplicity, comparing respective
groups to the HSFD control group (*P <0.05, **P <0.01, and ***P <0.001).
attenuated endothelium-dependent and -independent vasodila-
tion observed in HSFD SHR-SP (Table 3). Contractile responses
to phenylephrine were not altered between any treatment groups
(Table 3).
As compared to ND SHR-SP, chronic HSFD did not alter
the direct vasodilatory effects of the sGC stimulator BAY 60-
4552 [EC50 75± 16 nM and Emax 110± 2% vasodilation in ND
(n = 15); EC50 54± 14 nM and Emax 111± 2% vasodilation in
HSFD (n = 8); Figure 8C] or the sGC activator GSK2181236A
[EC50 270± 70 nM and Emax 110± 3% vasodilation in ND
(n = 15); EC50 321± 168 nM and Emax 110± 7% vasodilation
in HSFD (n = 6); Figure 8D]. These results are in contrast to
the blunted vasodilatory responses seen with the NO-dependent
vasodilators carbachol and SNP (Table 3; Figures 8A,B).
DISCUSSION
In the present study, we compared the effects of the sGC stimu-
lator BAY 60-4552 with those of the sGC activator GSK2181236A
on cardiovascular physiology in acute and chronic models of car-
diovascular disease associated with oxidative stress. The main
ﬁndings are: (1) in acute coronary artery I/R rats, pre-treatment
with either compound did not offer cardioprotection, (2) in
SHR-SP, both compounds improved survival and provided partial
protection against chronic HSFD-induced end-organ damage, (3)
GSK2181236A,but not BAY 60-4552, attenuated cardiac hypertro-
phy in a blood pressure-independent manner, and (4) the ex vivo
vasodilatory effects of the NO-dependent vasodilators carbachol
and SNP, but not the NO-independent vasodilators BAY 60-4552
or GSK2181236A, were attenuated by chronic HSFD in SHR-SP,
indicating that impaired NO-bioavailability and not the oxidative
state of sGC is responsible for the vascular dysfunction observed in
this disease model. Together, these results indicate that the oxida-
tion state of sGC in HSFD SHR-SP might be differentially altered
between tissues. If sGC is oxidized to a greater extent in the heart
compared to the vasculature, then sGC activation might be advan-
tageous over sGC stimulation for mitigating cardiac hypertrophy
associated with cardiovascular disease.
GSK2181236A was originally identiﬁed following a high
throughput screen for compounds which increase the enzymatic
activity of sGC. Subsequentmechanistic studies usingODQ,a sGC
heme-oxidant, indicated that GSK2181236A functions as a sGC
“activator” (i.e., it increases the enzyme activity of the oxidized,
NO-insensitive form of sGC in a heme-independent manner).
Speciﬁcally, consistent with the effects of ODQ on other sGC acti-
vators (Stasch et al., 2002b, 2006; Schindler et al., 2006; Zhou et al.,
2008), ODQ pretreatment of rat vascular smooth muscle cells or
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Table 3 | Effects of chronic GSK2181236A or BAY 60-4552 treatment on vasoactivity of SHR-SP isolated aorta.
Treatment group Phenylephrine Carbachol Sodium nitroprusside
EC50 (nM) Emax (% KCl) EC50 (nM) Emax (% reversal
of PE tone)
EC50 (nM) Emax (% reversal
of PE tone)
ND (n=14) 67±6 90±4 119±15 85±3*** 5±1** 108±4
HSFD (n=8) 72±11 83±10 260±74 47±11 16±3 103±9
HSFD+BAY 60-4552 (0.3mg/kg; n=6) 52±7 88±6 460±83 54±6 25±7 98±5
HSFD+BAY 60-4552 (3mg/kg; n=9) 52±8 89±7 328±41 67±6 26±10 112±3
HSFD+GSK2181236A (0.1mg/kg; n=4) 46±12 93±8 407±158 48±14 26±15 111±3
HSFD+GSK2181236A (1mg/kg; n=9) 76±16 91±8 385±89 59±4 19± 5 100±2
All values are expressed as mean±SEM. Emax values are expressed as percent reversal of phenylephrine (PE)-induced tone except for phenylephrine where values
are expressed as percent contractile response to 60mM KCl. Statistical comparisons of both pEC50 and Emax values were performed using ANOVA analysis with a
Dunnett’s post-test where **P<0.01 and ***P<0.001 vs. HSFD control SHR-SP.
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FIGURE 8 | Direct vasodilatory effects of various NO/sGC/cGMP pathway
modulators in aorta isolated from ND and HSFD SHR-SP. (A) As compared
to ND SHR-SP, the maximal vasodilatory response to carbachol, an
endothelium- and NO-dependent vasodilator, was suppressed in HSFD
SHR-SP. (B)The vasodilatory response to the endothelium-independent
vasodilator and NO-donor SNP was also inhibited in HSFD SHR-SP, being
right-shifted 3.5-fold as compared to the response observed in ND animals. In
contrast to the blunted vasodilatory responses seen with the NO-dependent
vasodilators carbachol and SNP, chronic HSFD did not alter the direct
vasodilatory effects of (C) the sGC stimulator BAY 60-4552 or (D) the sGC
activator GSK2181236A. All data are mean±SEM of 8–14 animals. Statistical
comparisons of vasodilatory pEC50 and Emax values are provided inTable 3.
vascular tissue augmented the functional effects (P-VASP forma-
tion and vasodilation, respectively) of GSK2181236A. Additional
characterization of GSK2181236A in cell-based assays revealed
that the interaction with sGC was at least 23-fold more potent
than any other non-sGC protein tested, further supporting the
utility of GSK2181236A as a pharmacological tool. BAY 60-4552,
a sGC“stimulator” (i.e., it increases the enzyme activity of only the
reduced,NO-sensitive formof sGC in a heme-dependentmanner)
currently being investigated in patients with biventricular heart
failure (Mitrovic et al., 2009), was used for comparative purposes.
As expected, in contrast to GSK2181236A, ODQ attenuated the
functional effects of BAY 60-4552 in vitro.
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One of the main adverse events associated with sGC stimu-
lation/activation is hypotension (Mitrovic et al., 2009; Erdmann
et al., 2010). This problem was mitigated in the current study
by selecting non-hypotensive and modestly hypotensive doses of
GSK2181236A and BAY 60-4552. Both doses are likely to be phys-
iologically relevant since sGC stimulators/activators have been
previously shown to elicit blood pressure-independent beneﬁcial
effects during chronic renal disease in subtotally nephrectomized
rats (Benz et al., 2007) and in aged spontaneously hypertensive
rats (Jones et al., 2009). Overall, both compounds elicited simi-
lar dose-dependent effects on heart rate and blood pressure, with
GSK2181236A being∼3-fold more potent. Equi-efﬁcacious doses
of both compounds were used for the I/R and SHR-SP studies.
Administration of GSK2181236A and BAY 60-4552 2 h prior to
cardiac I/R failed to reduce infarct size. This was an unexpected
ﬁnding considering that administration of NO-donors before car-
diac I/R consistently diminishes infarct size (Bolli, 2001; Schulz
et al., 2004). Although NO could exert cardioprotective effects via
non-sGC/cGMP mechanisms such as direct nitrosylation of pro-
teins (Stamler et al., 1992; Choi et al., 2002), it is widely accepted
that the cGMP/PKG pathway is the pivotal mechanism by which
NO mediates cardioprotection during I/R. Indeed, it has been
shown that natriuretic peptides and phosphodiesterase inhibitors
(which also modulate cGMP levels) reduce infarct size following
I/R (Burley et al., 2007). Whereas several decades of intense inves-
tigations support a protective role for cGMP in I/R injury, the
role of direct NO-independent sGC stimulation/activation during
cardiac I/R is only beginning to be established. The sGC activator
BAY 58-2667 improved cardiac function when administered 5min
prior to reperfusion following 60min global cardiac ischemia in
dogs (Korkmaz et al., 2009). Similarly, when administered 5min
prior to reperfusion following 30min regional ischemia, BAY
58-2667 decreased infarct size in rat (Krieg et al., 2009) and rab-
bit hearts (Krieg et al., 2009; Cohen et al., 2010). Interestingly,
inhibition of NO production with the eNOS inhibitor Nω-nitro-
l-arginine methyl ester (l-NAME) exerted differential effects in
these studies, blocking the cardioprotective effects BAY 58-2667
in rabbit (Cohen et al., 2010) but not in rats (Krieg et al., 2009).
These results indicate a PKG-independent role for endogenous
NO during I/R which could be species-dependent. In comparison
to these studies where drug treatment was initiated 5min prior to
reperfusion, we administered drug 2 h prior to the ischemic insult.
Additional studies are required to determine whether or not the
timing of drug administration or another factor is responsible for
the lack of cardioprotection observed in the present study.
Similar to previous studies, HSFD in SHR-SP induced a pro-
gressive,malignant hypertension with subsequent development of
renal dysfunction (microalbuminuria), mild cardiac hypertrophy,
and increased morbidity/mortality (Kerr et al., 1999; Barone et al.,
2001; Behr et al., 2001; Ma et al., 2001). The gene expression pro-
ﬁle observed in this study (increased ANF, α-skeletal actin, and
TGF-β1 and decreased α-MHC expression) was consistent with
maladaptive cardiac remodeling. Endothelial dysfunction, result-
ing from increased reactive oxygen species (ROS; e.g., superoxide
and peroxynitrite, the reactive nitrogen intermediate), reduced
bioavailable NO, or impaired NO-induced activation of oxidized
sGC, contributes to the development and progression of this
chronic hypertension and is likely a responsiblemechanism for the
hypertension-induced end-organ damage in this model (McIntyre
et al., 1997, 1999; Ma et al., 2001; Ju et al., 2003; Stasch et al., 2006).
Considering that the vasorelaxation and cardiac and renal pro-
tective effects of the sGC activator BAY 58-2667 were potentiated
under pathophysiological and oxidative stress conditions (Stasch
et al., 2006) and that removal of the sGC heme moiety or its
inactivation by oxidation strongly diminished the ability of sGC
stimulators to modulate sGC (Evgenov et al., 2006), it has been
hypothesized that pharmacological enhancement of the NO/sGC
pathway via sGC activators, not stimulators, would be the more
effective therapy for prevention and treatment of cardiovascu-
lar disease in the presence of excess ROS. This hypothesis has
not previously been tested comprehensively in vivo. In contrast to
expectations, however, improvement of endothelial function was
not potentiated by sGC activation as compared to sGC stimu-
lation. Instead, the vasorelaxation, blood pressure lowering, and
renal protective effects of the sGC stimulator BAY 60-4552 were
similar to or slighter greater than that of the sGC activator,
GSK2181236A, at the doses examined in this study. Overall, these
results suggest that the oxidation state of sGC capable of modu-
lating blood pressure and renal function is not altered to an extent
necessary to exploit the differing mechanisms of actions of these
pharmacological tools.
Interestingly, however, GSK2181236A, but not BAY 60-4552,
attenuated cardiac hypertrophy in a blood pressure-independent
fashion. These results suggest that sGC in cardiac tissue might be
oxidized to a level sufﬁcient to distinguish between sGC stimu-
lation and activation. Growing evidence suggests that ROS play
a pathophysiological role in the development of cardiac hyper-
trophy (see Seddon et al., 2007 for review), and indicates that
sGC activation might be advantageous over sGC stimulation
for mitigating maladaptive cardiac hypertrophy associated oxida-
tive stress. However, additional studies are required to elucidate
regional differences in sGC oxidation state.
The vasodilatory responses to compounds which modulate
the NO/sGC pathway at different points were investigated in
HSFD SHR-SP to help elucidate the mechanism(s) responsi-
ble for the vascular dysfunction. The vasodilatory responses
to the endothelium-dependent vasodilator carbachol and the
endothelium-independent vasodilator SNP were attenuated by
HSFD, consistent with previous observations (Ju et al., 2003;
Willette et al., 2009). These results alone could be explained by
multiple impairments in the NO/sGC pathway, including reduced
NO production, excessive NO degradation/neutralization, sGC
oxidation, altered phosphodiesterase activity, etc., and thus do
not clarify the mechanism for the impaired vasodilation. In con-
trast to NO-dependent vasodilation, however, the vasodilatory
responses to the NO-independent compounds BAY 60-4552 and
GSK2181236A were unaltered by HSFD. Taken together, three
important conclusions can be made. First, the mechanism respon-
sible for the impaired vasodilation is upstream of sGC and is
likely reduced NO-bioavailability due to the high levels of oxida-
tive stress and subsequent peroxynitrite formation associated with
HSFD in SHR-SP (Ma et al., 2001). Second, the level of oxidative
stress in this model is high enough to inactivate NO, but not high
enough to alter the oxidation state of sGC to a point necessary to
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impact the vasodilatory effects of direct (NO-independent) sGC
stimulators or activators. Rather, a level of sGCoxidation seenwith
10μM ODQ is likely necessary to impact NO-independent sGC
stimulator/activator-mediated vasodilation. As such, it is ques-
tionable whether or not the ODQ results represent a biochemical
artifact or a pathophysiological state. Interestingly, in contrast to
our results with GSK2181236A, Stasch et al. (2006) have shown
that the vasodilatory effects of a different sGC activator, BAY
58-2667, are potentiated under pathophysiological conditions in
animal models [aged SHR, hyperlipidemic (WHHL) rabbits and
atherosclerotic (ApoEl−/−) mice] and humans (mesocolon arter-
ies taken from patients with type 2 diabetes). The precise rea-
son for this discrepancy is unknown, but could be the result of
different animal models or compounds. Indeed, although both
GSK2181236A and BAY 58-2667 are sGC activators with struc-
tural similarities, their precise mechanism(s) of action might
differ. Additional studies are necessary to elucidate these discrep-
ancies. Third, consistent with the in vivo hemodynamic ﬁndings,
the hypothesis that sGC activation offers a therapeutic advan-
tage over sGC stimulation is not necessarily correct. Although
this hypothesis appears accurate when comparing NO-mediated
stimulationof sGC (e.g., viamuscarinic receptor activationorNO-
donors) with sGC activators (e.g., BAY 58-2667; Stasch et al., 2006,
GSK2181236A),other thandifferential effects on cardiachypertro-
phy, there was no clear differentiation between NO-independent
sGC stimulation and activation in the present study. These ﬁndings
emphasize that additional studies which directly compare NO-
independent sGCstimulatorswith activators arenecessary inorder
to better predict which class of agents might offer a therapeutic
advantage in a particular patient population.
In summary, the present study is the ﬁrst to compare a NO-
independent sGC stimulator (BAY 60-4552) with a sGC activator
(GSK2181236A) directly and comprehensively both in vitro and
in vivo. Whereas neither compound attenuated acute cardiac I/R
injury, both provided dose-dependent levels of protection against
HSFD-induced end-organ damage in SHR-SP, a model associated
with profound oxidative stress, hypertension, and renal dysfunc-
tion. Isolated artery dilation studies indicate that reduced NO-
bioavailability and not the oxidation state of sGC is responsible
for the HSFD-induced impaired vasodilation, and thus provide a
rationale as to why the hypotensive effects of sGC activation was
not potentiated. In contrast, the differential effects of sGC stimula-
tion and activation onHSFD-induced cardiac hypertrophy suggest
that the oxidative state of sGC is altered to a greater degree in car-
diac than vascular tissue. Overall, these results suggest that the
vasorelaxation, blood pressure, and end-organ protective effects
of sGC activators can be clearly differentiated from those of NO-
donors, but not from those of sGC stimulators in rodent models of
oxidative stress. However, sGC activation might be advantageous
over sGC stimulation for mitigating cardiac hypertrophy associ-
ated with cardiovascular disease. Additional studies designed to
further deﬁne the pharmacological differences between sGC stim-
ulators and sGC activators will be necessary to understand the
potential clinical differentiation of these two classes of agents.
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